Table 2.
Acute mortality after myocardial infarction in patients with type 2 diabetes mellitus treated with oral antidiabetic drugs including sulfonylureas and in normal subjects
| Author | Non-diabetic | Type 2 diabetic patients with sulfonylureas* | Type 2 diabetic patients without sulfonylureas | Insulin | Deceased (%) | p Value | |||
| No. | Deceased (%) | No. | Deceased (%) | No. | Diet/other OAD† | ||||
| Soler et al34 | – | – | 129 | 59 (45.7) | 156 | 31 | 125 | 54 (34.6) | 0.068 |
| Rytter et al30 | 751 | 152 (20.2) | 54 | 27 (50.0) | 19 | 8 | 11 | 5 (26.3) | 0.023 |
| Garratt et al41 | – | – | 67 | 7 (11.0) | 118 | 48 | 70 | 28 (24.0) | 0.032 |
| Klamann et al38 | 357 | 72 (20.2) | 76 | 25 (32.9) | 89 | 42 | 37 | 29 (32.6) | 1.0 |
| Halkin et al36 | – | – | 121 | 19 (15.7) | 124 | 96 | 28 | 22 (17.7) | 0.73 |
p Value: χ2 test.
*Including chlorpropamide, tolbutamide, and glibenclamide.
†Including metformin and acarbose.
OAD, oral antidiabetic agents.